BioNexus Gene Lab Corp

BGLC Nasdaq SEC CIK 1737523
Follow BioNexus Gene Lab Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $47.9K −98.1% vs same quarter last year
Net income −$1.1M −48.7% vs same quarter last year
EPS, diluted −$0.39 +0.8% vs same quarter last year
Operating cash flow −$257.5K +79.2% vs same quarter last year
Revenue by quarter
$2.5M
$2.1M
$2.3M
$2.5M
$483.8K
$22.8K
$76.2K
$47.9K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$5M$0$5M$10M$15MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$7.4M−$3M
FY24$9.5M−$1.6M
FY23$9.8M−$2.6M
FY22$10.9M−$356K
FY21$13.4M$751.6K
FY20$11.4M$1.1M
FY19$127K−$246.5K
FY18$212.3K$26.5K
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−300%−200%−100%0%100%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2514.6%−39.9%−40.2%
FY2413.6%−16.5%−16.8%
FY2313.6%−26.5%−26.9%
FY2211.5%−2.7%−3.3%
FY2117%7.9%5.6%
FY2015.1%11.2%9.6%
FY1944%−217.2%−194.1%
FY1813.5%28.2%12.5%
FY17---
Free cash flowOperating cash flow minus capital expenditure
−$3M−$2M−$1M$0$1MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$1.9M
FY24−$2.3M
FY23−$2M
FY22$551.8K
FY21$6K
FY20$131.1K
FY19−$230.1K
FY18−$313.7K
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • BioNexus Gene Lab
  • Healthcare median
−200%−100%0%100%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBioNexus Gene LabHealthcare median
FY25−40.2%−30.6%
FY24−16.8%−47%
FY23−26.9%−58%
FY22−3.3%−80.4%
FY215.6%−71.8%
FY209.6%−62.2%
FY19−194.1%−46.2%
FY1812.5%−49.6%
FY17-−45.9%